Infosys, a global leader in technology, consulting and outsourcing, has launched a cloud-based version of its
Clinical Trial Supply Management (CTSM) solution. The new solution helps life sciences companies enhance efficiency of clinical trial processes by driving greater collaboration between pharmaceutical companies and contract research organizations (CROs).
This solution helps to improve the productivity of the overall drug development process. It also helps ensure the timely and accurate supply of drugs to patients at reduced costs. As a result, enterprises can price products competitively while adhering to the stringent standards required to bring products safely to consumers.
The new cloud-based version of the CTSM solution is an enhancement to the existing on-premise version of the CTSM solution – CTSM Add-On Suite 2.2 by Lodestone – that offers a complete set of tools to manage all aspects of complex clinical trials. This covers demand and supply planning as well as distribution across clinical sites. The on-premise version of the solution has been successfully managing clinical trial processes at a number of large global pharmaceutical companies across the U.S. and Europe.
- The new cloud-based version of the CTSM solution offers increased visibility across the clinical trial supply chain – driving greater manufacturing and warehouse efficiencies while further ensuring compliance. For example, enterprises can respond faster to changes in demand based on actual enrollment and patient turnaround during trials.
- The solution integrates easily with existing enterprise resource planning (ERP) systems, incorporating business processes and other unique requirements of clinical trials.
- Available on a pay-per-use basis, it will help pharmaceutical, biotech companies and CROs eliminate the need to invest in or manage expensive infrastructure dedicated to clinical trial management.
- With mobility-enabled transactions and remote access capabilities, the solution facilitates real-time data entry for faster decision making.
- The intuitive user interface helps users easily perform key business functions using version 5 of SAP’s user interface and encourages wider adoption of the solution.
- The CTSM Add-On Suite 2.2 by Lodestone has been certified by SAP as powered by the SAP NetWeaver® technology platform. The on-premise solution is now owned by Infosys, following its acquisition of Lodestone in 2012.
Infosys will be demonstrating the cloud-based version of CTSM and other solutions in booth 308 at the SAPPHIRE® NOW conference being held June 3-5 in Orlando
Gartner believes “end-to-end business processes for CTSCs tend to be highly fragmented, span multiple functions and involve multiple enterprises. Clinical trials are growing in scale and complexity, driving a need for business processes and systems that integrate the end-to-end activities, decisions and information across business functions”.
Manish Tandon, Senior Vice President and Head of the Life Sciences, Infosys
“The new cloud-based version of our CTSM solution helps life sciences enterprises gain critical competitive advantages through cost savings and productivity gains via efficient management of their clinical trial supply chains. It is a solution that benefits from our experience in the sector, leveraging the power of SAP technology, and delivered through a cloud-based service.”
Infosys is a global leader in consulting, technology and outsourcing solutions. We enable clients, in more than 30 countries, to stay a step ahead of emerging business trends and outperform the competition. We help them transform and thrive in a changing world by co-creating breakthrough solutions that combine strategic insights and execution excellence.
www.infosys.com to see how Infosys (NYSE: INFY), with US$ 8.25 billion in annual revenues and 160,000+ employees, is Building Tomorrow's Enterprise® today.
SAP, SAP NetWeaver, SAPPHIRE and all SAP logos are trademarks or registered trademarks of SAP AG in Germany and in several other countries.
All other product and service names mentioned are the trademarks of their respective companies.
Certain statements in this release concerning our future growth prospects are forward-looking statements regarding our future business expectations intended to qualify for the 'safe harbor' under the Private Securities Litigation Reform Act of 1995, which involve a number of risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. The risks and uncertainties relating to these statements include, but are not limited to, risks and uncertainties regarding fluctuations in earnings, fluctuations in foreign exchange rates, our ability to manage growth, intense competition in IT services including those factors which may affect our cost advantage, wage increases in India, our ability to attract and retain highly skilled professionals, time and cost overruns on fixed-price, fixed-time frame contracts, client concentration, restrictions on immigration, industry segment concentration, our ability to manage our international operations, reduced demand for technology in our key focus areas, disruptions in telecommunication networks or system failures, our ability to successfully complete and integrate potential acquisitions, liability for damages on our service contracts, the success of the companies in which Infosys has made strategic investments, withdrawal or expiration of governmental fiscal incentives, political instability and regional conflicts, legal restrictions on raising capital or acquiring companies outside India, and unauthorized use of our intellectual property and general economic conditions affecting our industry. Additional risks that could affect our future operating results are more fully described in our United States Securities and Exchange Commission filings including our Annual Report on Form 20-F for the fiscal year ended March 31, 2013 and on Form 6-K for the quarter ended December 31, 2013. These filings are available at
www.sec.gov. Infosys may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company's filings with the Securities and Exchange Commission and our reports to shareholders. In addition, please note that the date of this press release is mentioned at the beginning of the release, and any forward-looking statements contained herein are based on assumptions that we believe to be reasonable as of this date. The company does not undertake to update any forward-looking statements that may be made from time to time by or on behalf of the company unless it is required by law.
Gartner, “Roche Beats Complexity by Building End-to-End Clinical Trial Supply Chain” Todd Applebaum, Barry Blake, 5 April 2012